Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179834 | 0.86 | F2 (0.53) | MTNR1AMTNR1BF2FFAR1KDM4E | |
| SCHEMBL31555289 | 0.86 | F2 (0.56) | MTNR1AMTNR1BF10F2 | |
| SCHEMBL6772943 | 0.85 | F10 (0.52) | MTNR1AMTNR1BF10F2SLC6A2 | |
| SCHEMBL31619581 | 0.82 | TAAR1 (0.54) | FFAR1CYP1A2TAAR1KDM4EL3MBTL1 | |
| SCHEMBL19432998 | 0.82 | TAAR1 (0.54) | FFAR1CYP1A2TAAR1KDM4EL3MBTL1 | |
| SCHEMBL13744616 | 0.81 | TAAR1 (0.56) | FFAR1CYP1A2TAAR1KDM4EL3MBTL1 | |
| SCHEMBL31483355 | 0.81 | TAAR1 (0.49) | FFAR1CYP1A2TAAR1KDM4EL3MBTL1 | |
| SCHEMBL3168923 | 0.80 | TAAR1 (0.51) | FFAR1CYP1A2TAAR1KDM4EL3MBTL1 | |
| SCHEMBL3162848 | 0.79 | CYP1A2 (0.47) | FFAR1CYP1A2TAAR1KDM4EL3MBTL1 | |
| SCHEMBL1369571 | 0.79 | L3MBTL1 (0.52) | MTNR1AMTNR1BF10F2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | MTNR1A 2887/4885MTNR1B 2529/4885F10 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.